SCHEMBL5482300

SCHEMBL5482300

CC(=O)Nc1ccc(C2(c3ccc(NC(C)=O)cc3)C(=O)Nc3c2ccc2c(C)c[nH]c32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
HTT P42858 2/20 0.41
CNR1 P21554 1/20 0.41
GPR35 Q9HC97 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA9 Q16790 2/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
NPC1 O15118 1/20 0.34
MAOA P21397 1/20 0.34
HPGD P15428 2/20 0.34
LMNA P02545 1/20 0.34
CYP2C9 P11712 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5474652 0.83 CNR1 (0.59) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5486236 0.81 CNR1 (0.43) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5488447 0.79 CNR1 (0.41) HTTCNR1GPR35GPR55TDP1
SCHEMBL5485863 0.78 HTT (0.67) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5478939 0.76 SMN1; SMN2 (0.56) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5482648 0.75 SMN1; SMN2 (0.62) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5488536 0.73 SMN1; SMN2 (0.55) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5479179 0.71 SMN1; SMN2 (0.53) SMN1; SMN2HTTCNR1GPR35GPR55
SCHEMBL5474337 0.67 SMN1; SMN2 (0.60) SMN1; SMN2HTTTDP1CA12CA1
SCHEMBL5478145 0.67 SMN1; SMN2 (0.60) SMN1; SMN2HTTTDP1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 SMN1; SMN2 234/4885HTT 1880/4885CNR1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.